Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
CRSP compared with SPGI: revenue, margins and what each company keeps, and the suppliers and customers both name
CRSP
CRISPR Therapeutics AG
Change
Mkt cap
Revenue
Revenue
SPGI
S&P Global Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
CRSP
CRISPR Therapeutics AG
vs
SPGI
S&P Global Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
CRSP, solid
SPGI, dashed
Supply-chain overlap
Revenue flow
CRSP: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only CRSP
5
LLY
Eli Lilly
customer
VRTX
Vertex
customer
VERX
Vertex Pharmaceuticals
customer
ACET
Adicet Bio
customer
1 more · CRSP chain
›
Shared
0
No shared counterparties.
Only SPGI
31
DKS
Dick's Sporting Goods
customer
JLL
Jones Lang Lasalle
customer
ALLY
Ally Financial
customer
VMI
Valmont Industries
customer
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
27 more · SPGI chain
›
CRSP
CRISPR Therapeutics AG
Change
50.08
▲
+3.13%
· post 50.00
Mkt cap
$4.9B
Revenue
$13M
Q3 FY26
Revenue
$4M
FY25
SPGI
S&P Global Inc.
Change
468.65
▼
−0.80%
· post 467.75
Closed
Nov 6 '26
Mkt cap
$135.6B
Revenue
$3.7B
Q3 FY26
Revenue
$15.3B
FY25
vs
Compare
Closed
Nov 6 '26
CRSP
CRISPR Therapeutics AG
vs
SPGI
S&P Global Inc.
50.08
▲
+3.13%
post 50.00
Price
468.65
▼
−0.80%
post 467.75
$4.9B
Mkt cap
$135.6B
Q3 FY26
$13M
Revenue
$3.7B
Q3 FY26
FY25
$4M
Revenue
$15.3B
FY25
Change
Change
CRSP
50.08
▲
+3.13%
vs
SPGI
468.65
▼
−0.80%
Closed
Nov 6 '26